Polynucleotide News and Research

RSS

What are the current challenges and future directions of mRNA nanomedicine?

Researchers presented challenges related to the clinical translation of messenger ribonucleic acid (mRNA) technology, recent innovations and future directions to improve the clinical efficacy of mRNA nanomedicine.

15 Nov 2022

Study shows competitive fitness of emerging SARS-CoV-2 variants linked to their distinctiveness relative to identified lineages

Researchers defined a novel polynucleotide-based Distinctiveness metric to capture the proteome-level differences of emerging SARS-CoV-2 variants and lineages against all previously identified ones.

11 Mar 2022

Omicron will outcompete Delta variant for next 4-5 months globally: Genome study

A new study published in the pre-print server medRxiv* hypothesized that the emergence of more immune invasive or transmissible variants of SARS-CoV-2 was associated with increased genetic distinctiveness from the original or previous strains.

29 Dec 2021

New technique helps measure dNTP concentrations with greater sensitivity

A highly sensitive and easy-to-use technique applicable for tissue samples can be useful, for example, to researchers specialised in mitochondrial diseases and cancer.

24 Jun 2020

Horizon 2020 program selects Precision NanoSystems’ NanoAssemblr platform to develop RNA medicines

Precision NanoSystems NanoAssemblr platform has been selected for the controlled manufacture of nanomedicines as part of the multinational B-SMART (Brain-Specific, Modular and Active RNA Therapeutics) translational research project.

From Precision NanoSystems Inc. 3 Apr 2017

Illumina's new patent infringement suit targets Complete Genomics' cPal read technology

Illumina (NASDAQ:ILMN) announced today that the company has filed an additional patent infringement suit against Complete Genomics, Inc. Illumina is seeking all available remedies, including injunctive relief.

From Illumina, Inc. 18 Jun 2012

Discovery sheds light on what happens in cells when DNA is damaged

A research group in the Faculty of Medicine & Dentistry at the University of Alberta is hoping its latest discovery could one day be used to develop new therapies that target certain types of cancers.

13 Feb 2012

USPTO grants two additional patents to Ryogen

Ryogen LLC, a genomic research and development company focusing on genes with applications in biomedical research, has been awarded two additional patents on human genes.

20 Oct 2010

Scientists identify role of PNPASE in regulating RNA import into mitochondria

Researchers at UCLA's Jonsson Comprehensive Cancer Center and the departments of Chemistry and Biochemistry and Pathology and Laboratory Medicine have uncovered a role for an essential cell protein in shuttling RNA into the mitochondria, the energy-producing "power plant" of the cell. The import of nucleus-encoded small RNAs into mitochondria is essential for the replication, transcription and translation of the mitochondrial genome, but the mechanisms that deliver RNA into mitochondria remain poorly understood.

7 Aug 2010

VCU researchers discover mechanism that regulates gene expression and growth in melanoma cells

Virginia Commonwealth University researchers have discovered a mechanism by which an enzyme regulates gene expression and growth in melanoma cells, a finding that could someday lead to more effective drugs to attack cancers and make them more treatable.

18 Jun 2010

U.S. Patent and Trademark Office awards new patent for Ryogen

Ryogen LLC, a genomic start-up company, has been awarded a new patent titled “Isolated Genomic Polynucleotide Fragments from Chromosome 7”.

12 Nov 2009

Relationship found between DNA nanomechanics and damage

It has long been known that UV light can damage DNA, reducing its ability to replicate and interact with proteins, and often resulting in the development of skin cancers.

25 Apr 2007

Vical Incorporated issued two Canadian patents

Vical Incorporated announced today the issuance of two Canadian patents on the company's core technology, which involves direct administration of polynucleotide genetic material such as DNA or RNA.

29 Mar 2005

Discovery gives clinicians new targets for making existing therapies more effective and developing drugs to inhibit the growth of cancers

A team of researchers at the University of Alberta in Edmonton and the Samuel Lunenfeld Research Institute in Toronto have discovered how a key enzyme involved in repairing DNA is put together and how it works--a development that opens up new therapies for making cancer cells more vulnerable to attack.

3 Mar 2005

Genomics tools provide clues to what causes 400 million cases of gastrointestinal disease each year

In a study that could benefit medical and food-safety research, scientists have used comparative genomics tools to find clues about why some strains of the bacterium Campylobacter – which each year cause more than 400 million cases of gastrointestinal disease – are more virulent than others.

4 Jan 2005